Aquestive Therapeutics, Inc.
AQSTNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 16, 2026 close
- Market cap
- $507.48M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.93$7.55
- Volume (live)
- -
- Avg. volume (3M)
- 2.31M
Aquestive Therapeutics (AQST) Stock Price & Financial Analysis
Aquestive Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $3.75 - $4.10 |
|---|---|
| 52-Week High | $7.55 |
| 52-Week Low | $2.93 |
| Open | $4.09 |
| Volume (last close) | 5.25M |
| Average Volume (3M) | 2.31M |
| Revenue (TTM) | 54.09M |
|---|---|
| Net Income (TTM) | -78.23M |
| Free Cash Flow (TTM) | -45.95M |
| EPS (TTM) | −$0.65 |
| Profit Margin | -144.63% |
| Operating Margin | -97.52% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 507.48M |
|---|---|
| Shares Outstanding | 124.99M |
| Price to Sales (P/S) | 9.38 |
| Price to Book (P/B) | -8.97 |
| EV/EBITDA | -9.09 |
| 50-Day MA | $4.71 |
|---|---|
| 200-Day MA | $4.29 |
| 1-Year Change | −42.66% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Aquestive Therapeutics at a Glance
As of the Oct 16, 2026 close, Aquestive Therapeutics (AQST) has a market capitalization of $507.48M. The stock trades at 9.4× sales. Over the trailing twelve months it lost $78.23M on revenue of $54.09M and burned $45.95M of free cash flow. Revenue grew 22.6% year over year.
As of its latest reported balance sheet, it holds $98.49M in cash and securities against $50.69M of debt, a net cash position of $47.80M.
Aquestive Therapeutics does not currently pay a dividend.
The share price is down 42.7% over the past year. At $3.78 (the Oct 16, 2026 close) it sits within its 52-week range of $2.93 to $7.55, below its 200-day moving average of $4.29.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $8.67, 129.4% above the Oct 16, 2026 close.
Frequently Asked Questions About Aquestive Therapeutics
What is the current stock price for AQST?
As of the Oct 16, 2026 close, AQST stock trades at $3.78. The 52-week range is $2.93–$7.55, with a day range of $3.75–$4.10.
What is the P/E ratio for AQST?
The P/E ratio (Price-to-Earnings) for AQST is shown in the Key Statistics section. This valuation metric helps compare Aquestive Therapeutics, Inc. to industry peers.
Does AQST pay dividends?
Aquestive Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for AQST?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for AQST is Buy. The average 12-month price target is $8.67, a 129.4% upside from the Oct 16, 2026 close of $3.78.
What is the market cap of AQST?
As of the Oct 16, 2026 close, Aquestive Therapeutics's market capitalization is $472.5M, classifying it as a small-cap company. Aquestive Therapeutics operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.